Abstract
Memantine is primarily prescribed for treating moderate to severe Alzheimer’s disease by modulating glutamate, a key neurotransmitter involved in cognitive functions like memory and learning. By blocking excessive glutamate activity at NMDA receptors, memantine helps improve cognitive function and slow symptom progression in Alzheimer’s patients. In this study, solvent evaporation was used in the formulation of memantine in order to increase its bioavailability and sustain its release. Chitosan, HPMC, a mucoadhesive polymer, carbopol, a sensitive to pH polymer and propyle glycol, a permeation enhancer, were all incorporated in the formulation. All formulations underwent evaluation for moisture content, folding endurance, swelling index, mucoadhesive strength and drug content. Drug release profiles were assessed through in-vitro diffusion studies. Results indicated that increasing concentrations of polymers led to higher mucoadhesive strength, consequently enhancing Memantine release from the system. The optimal formulation(F9), with carefully balanced polymer concentrations, demonstrated more resident time, sustained drug release and improved bioavailability.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call